NCT00613730View on ClinicalTrials.gov

Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Cancer of PancreasCancer of the PancreasPancreas CancerPancreatic Cancer
Interventions
DRUG

Gemcitabine

Intravenous administration

DRUG

panitumumab

Intravenous administration

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00613730 - Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint | Biotech Hunter | Biotech Hunter